Modern ways to reduced mortality of myocardial infarction. What should be done?
https://doi.org/10.18699/SSMJ20230501
Abstract
Myocardial infarction is a formidable manifestation of coronary artery disease and accounts for one third of deaths associated with coronary disease. In Russia, from 400 to 500 thousand patients with acute coronary syndrome are hospitalized annually, about half of them with myocardial infarction (MI). The dynamics of the number of hospitalized patients in recent years indicates its reduction. Short-term mortality (30-day, including hospital mortality) after acute MI has decreased significantly over the past 50 years: in absolute terms from 30 % in 1950 to 5–8 % at present. However, long-term mortality after MI did not improve. Moreover, in recent years, the rate of decline in 30-day mortality from MI has decreased significantly, almost reaching a “plateau” over the past 15 years. It has been established that in terms of the impact on survival, disability and quality of life of the working population, MI is an important not only medical but also social problem. This review of the literature discusses changes in approaches to reducing mortality in MI, as well as the main events in evidence-based cardiology over the past 50 years, which have made it possible to effectively manage the risk of death in this category of patients.
About the Authors
O. L. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
doctor of medical sciences, professor, academician of the RAS
650002, Kemerovo, Sosnovy Boulevard, 6
T. B. Pecherina
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
doctor of medical sciences
650002, Kemerovo, Sosnovy Boulevard, 6
References
1. Shalnova S.A., Drapkina O.M., Kutsenko V.A., Kapustina A.V., Muromtseva G.A., Yarovaya E.B., Balanova Yu.A., Evstifeeva S.E., Imaeva A.E., Shlyakhto E.V., … Chernykh T.M. Myocardial infarction in the population of some Russian regions and its prognostic value. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022;27(6):9–19. [In Russian]. doi: 10.15829/1560-4071-2022-4952
2. Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Cheng S., Delling F.N., … American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and stroke statistics – 2021 update: A report from the American Heart Association. Circulation. 2021;143(8):254–743. doi: 10.1161/CIR.0000000000000950
3. Mechanic O.J., Gavin M., Grossman S.A. Acute myocardial infarction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/29083808/
4. Writing Committee Members, Gulati M., Levy P.D., Mukherjee D., Levy P.D., Mukherjee D., Amsterdam E., Bhatt D.L., Birtcher K.K., Blankstein R., … Shaw L.J. 2021 AHA/ACC/ASE/CHEST/SAEM/ SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2021;78(22):2218–2261. doi: 10.1016/j.jacc.2021.07.052
5. Timonin S., Shkolnikov V.M., Andreev E., Magnus P., Leon D.A. Evidence of large systematic differences between countries in assigning ischaemic heart disease deaths to myocardial infarction: the contrasting examples of Russia and Norway. Int. J. Epidemiol. 2022;50(6):2082–2090. doi: 10.1093/ije/dyab188
6. Alekyan B.G., Boytsov S.A., Manoshkina E.M., Ganyukov V.I. Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016–2020. Kardiologiya = Cardiology. 2021;61(12):4–15. [In Russian]. doi: 10.18087/cardio.2021.12.n1879
7. Roth G.A., Vaduganathan M., Mensah G.A. Impact of the COVID-19 pandemic on cardiovascular health in 2020: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2022;80(6):631–640. doi: 10.1016/j.jacc.2022.06.008
8. Laforgia P.L., Auguadro C., Bronzato S., Durante A. The reduction of mortality in acute myocardial infarction: from bed rest to future directions. Int. J. Prev. Med. 2022;13:56. doi: 10.4103/ijpvm.IJPVM_122_20
9. Szummer K., Wallentin L., Lindhagen L., Alfredsson J., Erlinge D., Held C., James S., Kellerth T., Lindahl B., Ravn-Fischer A., … Jernberg T. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur. Heart. J. 2018;39(42):3766–3776. doi: 10.1093/eurheartj/ehy554
10. Сhazov E.I., Matveeva L.S., Mazaev A.V., Sargin K.E., Sadovskaya G.V., Ruda M.I. Intracoronary administration of fibrinolysin in acute myocardial infarction. Terapevticheskiy arkhiv = Therapeutic Archive. 1976;48(4):8–19. [In Russian].
11. Levine S.A., Lown B. “Armchair” treatment of acute coronary thrombosis. J. Am. Med. Assoc. 1952;148(16):1365–1369. doi: 10.1001/jama.1952.02930160001001
12. Norris R.M., Bensley K.E., Caughey D.E., Scott P.J. Hospital mortality in acute myocardial infarction. Br. Med. J. 1968;3(5611):143–146. doi: 10.1136/bmj.3.5611.143
13. Julian D.G. Treatment of cardiac arrest in acute myocardial ischaemia and infarction. Lancet. 1961;2(7207):840–844. doi: 10.1016/S01406736(61)90738-3
14. Goble A.J., Sloman G., Robinson J.S. Mortality reduction in a coronary care unit. Br. Med. J. 1966;1(5494):1005–1009. doi: 10.1136/ bmj.1.5494.1005
15. Bloomfield D.K., Slivka J., Vossler S., Edelstein J. Survival in acute myocardial infarction before and after the establishment of a coronary care unit. Chest. 1970;57(3):224–229. doi: 10.1378/chest.57.3.224
16. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–1172. doi: 10.1161/01.CIR.81.4.1161
17. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;327(8478):397–402. doi: 10.1016/S0140-6736(86)92368-8
18. Grines C.L., Browne K.F., Marco J., Rothbaum D., Stone G.W., O’Keefe J., Overlie P., Donohue B., Chelliah N., … Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N. Eng. J. Med. 1993;328(10):673–679. doi: 10.1056/NEJM199303113281001
19. Nordmann A.J., Bucher H., Hengstler P., Harr T., Young J. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev. 2005;(2):CD005313. doi: 10.1002/14651858.CD005313
20. Popma J.J., Leon M.B., Moses J.W., Holmes D.R., Cox N., Fitzpatrick M., Douglas J., Lambert C., Mooney M., Yakubov S., … SIRIUS Investigators. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation. 2004;110(25):3773–3780. doi: 10.1161/01.CIR.0000150331.14687.4B
21. Moreno R. Drug-eluting stents and other anti-restenosis devices. Rev. Esp. Cardiol. 2005;58(7):842–862. doi: 10.1157/13077236
22. Nauta S.T., Deckers J.W., Akkerhuis K.M., van Domburg R.T. Shortand long-term mortality after myocardial infarction in patients with and without diabetes: Changes from 1985 to 2008. Diabetes Care. 2012;35(10):2043–2047. doi: 10.2337/dc11-2462
23. Savarese G., Savonitto S., Lund L.H., Paolillo S., Marciano C., Dellegrottaglie S., Parente A., Trimarco B., Luscher T.F., Perrone-Filardi P. Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. Eur. Heart J. Cardiovasc. Pharmacother. 2016;2(4):218–228. doi: 10.1093/ehjcvp/pvw011
24. Abusnina W., Baral N., Seri A., Ben-Dor I., Alkhouli M., Monteleone P., Haddad E., Goldsweig A.M., Paul T.K. Safety and efficacy of ultra short-duration dual antiplatelet therapy after percutaneous coronary interventions: A meta-analysis of randomized controlled trials. Curr. Probl. Cardiol. 2022;47(10):101295. doi: 10.1016/j.cpcardiol.2022.101295
25. Selvaraj V., Chatterjee S., Hirai T., Abbott J.D., Bavishi C. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Catheter. Cardiovasc. Interv. 2022;100(7):1151–1158. doi: 10.1002/ccd.30467
26. Durante A., Camici P.G. Novel insights into an “old” phenomenon: The no reflow. Int. J. Cardiol. 2015;187:273–280. doi: 10.1016/j.ijcard.2015.03.359
27. Kloner R.A., Ganote C.E., Jennings R.B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974;54(6):1496– 1508. doi: 10.1172/JCI107898
28. Ndrepepa G., Tiroch K., Fusaro M., Keta D., Seyfarth M., Byrne R.A., Pache J., Alger P., Mehilli J., Schömig A., Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 2010;55(21):2383–2389. doi: 10.1016/j.jacc.2009.12.054
29. Leonardi S., Montalto C., Carrara G., Casella G., Grosseto D., Galazzi M., Repetto A., Tua L., Portolan M., Ottani F., … ACS Clinical Governance Programme Investigators. Clinical governance of patients with acute coronary syndromes. Eur. Heart. J. Acute. Cardiovasc. Care. 2022;30;11(11):797–805. doi: 10.1093/ehjacc/zuac106
30. Averkov O.V., Duplyakov D.V., Gilyarov M. Yu., Novikova N.A., Shakhnovich R.M., Yakovlev A.N., Abugov S.A., Alekyan B.G., Arkhipov M.V., Barbarash O.L., … Yakushin S.S. 2020 clinical practice guidelines for acute st-segment elevation myocardial infarction. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(11):251–310. [In Russian]. doi: 10.15829/1560-4071-2020-4103
31. Barbarash O.L., Duplyakov D.V., Zateishchikov D.A., Panchenko E.P., Shakhnovich R.M., Yavelov I.S., Yakovlev A.N., Abugov S.A., Alekyan B.G., Arkhipov M.V., … Yakushin S.S. Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021;26(4):149– 202. [In Russian]. doi: 10.15829/1560-4071-2021-4449
32. Cardarelli F., Bellasi A., Fang-Shu O., Shaw L.J., Veledar E., Roe M.T., Morris D.C., Peterson E.D., Klein L.W., Raggi P. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am. J. Cardiol. 2009;103(6):766–771. doi: 10.1016/j.amjcard.2008.11.033
33. Kite T.A., Kurmani S.A., Bountziouka V., Cooper N.J., Lock S.T., Gale C.P., Flather M., Curzen N., Banning A.P., McCann G.P., Ladwiniec A. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur. Heart. J. 2022;43(33):3148–3161. doi: 10.1093/eurheartj/ehac213
34. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., Falk V., Head S.J., … ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart. J. 2019;14(14):1435– 1534. doi: 10.4244/EIJY19M01_01
35. Saito Y., Kobayashi Y. Complete revascularization in acute myocardial infarction: a clinical review. Cardiovasc. Interv. Ther. 2023;38(2):177–186. doi: 10.1007/s12928-022-00907-6
36. Wood D.A., Cairns J.A., Wang J., Mehran R., Storey R.F., Nguyen H., Meeks B., Kunadian V., Tanguay J.F., Kim H.H., … COMPLETE Investigators. Timing of staged nonculprit artery revascularization in patients with ST-segment elevation myocardial infarction: COMPLETE Trial. J. Am. Coll. Cardiol. 2019;74(22): :2713–2723. doi: 10.1016/j.jacc.2019.09.051
37. Markov V.A., Duplyakov D.V., Konstantinov S.L., Klein G.V., Aksentev S.B., Platonov D.Yu., Vyshlov E.V., Ponomarev E.A., Rabinovich R.M., Makarov E.L., … Gerasimets EA. Fortelyzin in comparison with Metalyse for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;23(11):110–116. [In Russian]. doi: 10.15829/1560-4071-2018-11-110-116
38. Sricholwattana S., Chaipromprasit J., Kosum P. Prevalence and characteristics of non-ST-segment elevation in acute myocardial infarction with insignificant coronary artery disease. Eur. Heart. J. 2022;43(1):ehab849.067. doi: 10.1093/eurheartj/ehab849.067
39. Thygesen K., Alpert J.S., White H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction; Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., … Al-Attar N. Universal definition of myocardial infarction. Eur. Heart. J. 2007;28(20):2525–2538. doi: 10.1093/eurheartj/ehm355
40. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D.; Exeсutive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF). Task force for the universal definition of myocardial infarction. Fourth universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2018;72(18):2231–2264. doi: 10.1093/eurheartj/ehy462
41. Collinson P., Lindahl B. Type 2 myocardial infarction: the chimaera of cardiology? Heart. 2015;101(21):1697–1703. doi: 10.1136/heartjnl-2014307122
42. Baron T., Hambraeus K., Sundström J., Erlinge D., Jernberg T., Lindahl B.; TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart. 2015;101(2):101–106, doi: 10.1136/heartjnl-2014-306093
43. Saaby L., Poulsen T.S., Hosbond S., Larsen T.B., Pyndt Diederichsen A.C., Hallas J., Thygesen K., Mickley H. Classification of myocardial infarction: frequency and features of Type 2 myocardial infarction. Am. J. Medicine. 2013;126(9):789–797. doi: 10.1016/j.amjmed.2013.02.029
44. Hawatmeh A., Thawabi M., Aggarwal R., Abirami C., Vavilin I., Wasty N., Visveswaran G., Cohen M. Implications of misclassification of type 2 myocardial infarction on clinical outcomes. Cardiovasc. Revasc. Med. 2020;21(2):176–179. doi: 10.1016/j.carrev.2019.04.009
45. Saaby L., Poulsen T.S., Diederichsen A.C., Hosbond S., Larsen T.B., Schmidt H., Gerke O., Hallas J., Thygesen K., Mickley H. Mortality rate in type 2 myocardial infarction: observations from anunselected hospital cohort. Am. J. Med. 2014;127(4):295–302. doi: 10.1016/j.amjmed.2013.12.020
46. Jogu H.R., Arora S., Vaduganathan M., Qamar A., Pandey A., Chevli P.A., Pansuriya T.H., Ahmad M.I., Dutta A., Sunkara P.R., … Herrington D. Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clin. Cardiol. 2019;42(6):592–604. doi: 10.1002/clc.23182
47. Loccoh E.C., Joynt Maddox K.E., Wang Y., Kazi D.S., Yeh R.W., Wadhera R.K. Rural-urban disparities in outcomes of myocardial infarction, heart failure, and stroke in the United States. J. Am. Coll. Cardiol. 2022;79(3):267–279. doi: 10.1016/j.jacc.2021.10.045
Review
For citations:
Barbarash O.L., Pecherina T.B. Modern ways to reduced mortality of myocardial infarction. What should be done? Сибирский научный медицинский журнал. 2023;43(5):6-13. (In Russ.) https://doi.org/10.18699/SSMJ20230501
Views:
450
Email this article 